Initial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India - Multicentric, real-world study.

Autor: Singh DV; Retina Department, Vitreo-retinal Services, Eye-Q Superspecialty Eye Hospitals Gurugram, Haryana, India., Agarwal A; Retina Department, The Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (UAE).; Retina Department, The Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (UAE), Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA.; Department of Ophthalmology, Maastricht University Medical Center, Maastricht, The Netherlands., Goyal A; Retina Department, Giridhar Eye Institute, Ernakulum, Kerala, India., Shroff D; Retina Department, Shroff Eye Center, Kailash Colony, New Delhi, India., Singh J; Retina Department, Vitreo-retinal Services, The Eye Foundation, Coimbatore, Tamil Nadu, India., Kumar P; Department of Ophthalmology, Army Hospital Research Referral, Delhi Cantt, New Delhi, India., Reddy RR; Retina Department, Neo-Retina Eyecare Institute, Chapel Road Nampally Hyderabad, Telangana, India., Venkatesh R; Retina Department, Narayana Nethralaya Eye Hospital, Bengaluru, Karnataka, India., Narnaware S; Vitreoretina Department, Sarakshi Netralaya, Nagpur, Maharashtra, India., Joshi S; Retina Department, M M Joshi Eye Hospital, Gokul Road, Sadashiv Nagar Hubli, Karnataka, India., Singh DV; Retina Department, Vitreo-retinal Services, Eye-Q Superspecialty Eye Hospitals Gurugram, Haryana, India., Narula R; Retina Department, Smt Kanuri Santhamma Centre for Vitreo Retinal Diseases, L V Prasad Eye Institute Banjara Hills, Hyderabad, Telangana, India., Joshi A; Retina Department, Narayana Nethralaya Eye Hospital, Bengaluru, Karnataka, India., Agarwal A; Retina Department, The Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (UAE).; Retina Department, The Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (UAE), Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA.; Department of Ophthalmology, Maastricht University Medical Center, Maastricht, The Netherlands., Goyal A; Retina Department, Giridhar Eye Institute, Ernakulum, Kerala, India., Gupta C; Retina Department, Shroff Eye Center, Kailash Colony, New Delhi, India., Shroff D; Retina Department, Shroff Eye Center, Kailash Colony, New Delhi, India., Anantharaman G; Retina Department, Giridhar Eye Institute, Ernakulum, Kerala, India., Singh J; Retina Department, Vitreo-retinal Services, The Eye Foundation, Coimbatore, Tamil Nadu, India., Kumar P; Department of Ophthalmology, Army Hospital Research Referral, Delhi Cantt, New Delhi, India., Bawankule P; Vitreoretina Department, Sarakshi Netralaya, Nagpur, Maharashtra, India., Reddy RR; Retina Department, Neo-Retina Eyecare Institute, Chapel Road Nampally Hyderabad, Telangana, India., Jain R; Retina Department, Save Sight Centre, Adarsh Nagar, Delhi, India., Venkatesh R; Retina Department, Narayana Nethralaya Eye Hospital, Bengaluru, Karnataka, India., Tiwari R; Retina Department, Vitreo-retina Services, Tewari Eye Centre, Uttar Pradesh, India., Sugumar S; Retina Department, Neo-Retina Eyecare Institute, Chapel Road Nampally Hyderabad, Telangana, India., Gupta SR; Retina Department, Delhi Eye Care 4/17, Balraj Khanna Marg East Patel Nagar, New Delhi, India., Narnaware S; Vitreoretina Department, Sarakshi Netralaya, Nagpur, Maharashtra, India., Joshi S; Retina Department, M M Joshi Eye Hospital, Gokul Road, Sadashiv Nagar Hubli, Karnataka, India., Choudhary SP; Retina Department, Complete Eye Care Centre Manish Chamber, Mayur Vihar Phase-2, Delhi, India.
Jazyk: angličtina
Zdroj: Indian journal of ophthalmology [Indian J Ophthalmol] 2024 Dec 01; Vol. 72 (12), pp. 1786-1794. Date of Electronic Publication: 2024 Nov 29.
DOI: 10.4103/IJO.IJO_757_24
Abstrakt: Purpose: To evaluate the anatomic and visual outcomes and safety profile of initial Indian eyes with neovascular age-related macular degeneration (nAMD) treated with intravitreal injection (IVI) of brolucizumab.
Methods: This retrospective multicentric, real-world study enrolled consecutive eyes with nAMD that were treated with IVI brolucizumab after it was launched in India in October 2020. Data collected for each eye included best-corrected visual acuity (BCVA), central subfield thickness (CSFT), subretinal fluid (SRF), and intraretinal fluid (IRF) status at 6, 12, and 24 months follow-up. Also recorded were the lens status, treatment protocol, number of injections received before enrollment (in switch-over cases), total number of injections, and adverse effects noticed during the study period. Primary outcomes were change in BCVA, CSFT at follow-up visits, and incidence of intraocular inflammation (IOI). Secondary outcomes were profile of macular neovascularization, treatment protocols, mean number of injections, and maximum injection-free interval observed in eyes treated by pro-re-nata (PRN) protocol.
Results: In total, 331 eyes received a mean of 3.55 ± 1.83 injections. Most frequent treatment protocol was PRN (53%). BCVA data was available for 100%, 96%, and 74% eyes at 6, 12, and 24 months follow-up. BCVA and CSFT improved significantly (P < 0.001) at all follow-ups. Two hundred and seventy-six (83.38%) out of 331 eyes received more than one injection; out of these, 241 (87.3%) eyes that were treated by PRN protocol could achieve mean "maximum injection-free interval" of 19.43 ± 8.82 weeks. IOI and retinal vasculitis were reported in 2.11% (7/331) and 0.60% (2/331) eyes, respectively. None of the eyes with IOI or vasculitis lost any vision at the final follow-up.
Conclusion: This study demonstrated favorable visual and anatomic outcomes and safety profile for eyes with nAMD treated by IVI brolucizumab. Mean maximum injection-free interval in eyes treated with PRN was 19 weeks.
(Copyright © 2024 Indian Journal of Ophthalmology.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje